Company / Working Capital
Rapport Therapeutics, Inc. Working Capital History
FY2023-FY2024 · Annual data · Source: SEC filings
At a glance
Latest annual filing availableLatest Working Capital
$301.0M
FY2024
5-year range
$142.1M / $301.0M
FY2023-FY2024
Trend
+111.9%
vs FY2023
Sector context
#140 of 213
Health Care
What the data says
At $301M, Rapport Therapeutics, Inc.'s working capital ranks #140 of 213 in the Health Care sector.
Based on SEC 10-K filings.
$301M in FY2024.
Health Care sector context is included.
Working Capital over time
Growth rates
- 3-Year CAGR
- -
- 5-Year CAGR
- -
- 10-Year CAGR
- -
Sector benchmark
#140 of 213 in Health CareTop 66% of 213This company $301.0M Sector average $934.6M
▼
-67.8% below sector average
Key checks
Key Insights
- In FY2024, working capital increased 111.9% year-over-year.
- Ranks #140 out of 213 companies in the Health Care sector.
Company context
Key Data Points
- Low Piotroski F-Score: 2/9 (multiple financial health concerns)
- Altman Z-Score 13.36 (safe zone, above 2.9 threshold)
- High earnings quality (cash-backed earnings)
Data sourced from SEC EDGAR filings. Not investment advice.
Annual data
| Year | Working CapitalValue | YoY GrowthYoY |
|---|---|---|
| FY2024 | $301.0M | +111.9% |
| FY2023 | $142.1M | - |
As of FY2024 · SEC 10-K · Updated Feb 28, 2026